BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets lessened its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 60.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 196,225 shares of the biotechnology company's stock after selling 300,559 shares during the period. BNP Paribas Financial Markets owned about 0.09% of BioCryst Pharmaceuticals worth $1,476,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BCRX. KBC Group NV lifted its position in shares of BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock worth $77,000 after purchasing an additional 4,537 shares during the last quarter. R Squared Ltd purchased a new stake in BioCryst Pharmaceuticals during the 4th quarter worth about $48,000. China Universal Asset Management Co. Ltd. boosted its position in shares of BioCryst Pharmaceuticals by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 43,920 shares of the biotechnology company's stock worth $330,000 after acquiring an additional 4,129 shares in the last quarter. Choreo LLC acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth about $106,000. Finally, Rhumbline Advisers increased its holdings in shares of BioCryst Pharmaceuticals by 1.8% in the 4th quarter. Rhumbline Advisers now owns 309,132 shares of the biotechnology company's stock valued at $2,325,000 after acquiring an additional 5,615 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Up 1.9%

NASDAQ:BCRX traded up $0.20 during midday trading on Friday, reaching $10.59. The stock had a trading volume of 3,608,168 shares, compared to its average volume of 3,022,861. The stock has a market cap of $2.22 billion, a P/E ratio of -17.36 and a beta of 1.08. BioCryst Pharmaceuticals, Inc. has a 12-month low of $5.92 and a 12-month high of $11.11. The firm has a fifty day simple moving average of $8.38 and a two-hundred day simple moving average of $8.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. The firm's quarterly revenue was up 40.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.28 earnings per share. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on BCRX shares. JPMorgan Chase & Co. upped their price target on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Tuesday, May 6th. Royal Bank of Canada restated an "outperform" rating and set a $13.00 price objective (up previously from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. JMP Securities reiterated a "market outperform" rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Barclays boosted their price target on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research report on Wednesday, May 7th. Finally, Wedbush assumed coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective on the stock. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of "Buy" and a consensus price target of $16.56.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.